Traws Pharma

Listed: NASDAQ: TRAWHas an LEI2 legal entities

Facts

as of Nov 17, 2026

Targeting escape mutations in hematological cancers with first and best in class medicines.

Legal name
Traws Pharma, Inc.
Headquarters
Newtown, United States
Employees
51-200estimated range
Revenue
$12018 · SEC Form D 0001104659-19-033519
Legal entities
2 in 1 countries
Listing
NASDAQ: TRAW
Register numbers
NAME traws pharma inc
Website
trawspharma.com

These are the key facts about Traws Pharma on Alion as of Nov 17, 2026. Traws Pharma is headquartered in Newtown, United States. It has raised $15.8M in 3 funding rounds. The latest round is Venture - Series Unknown of $14M, announced in 2024.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Legal entity active
Traws Pharma, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Footprint

Hiring in 1 city in 1 country.

1Cities
1Countries
SiteTypeOpen rolesHires most forEngineering
Newtown United StatesHeadquarters0
Source: office addresses in postings and company registers

Financials

Funding rounds, investors and revenue on record.

$1Revenue2018
$15.8MTotal raised
Venture - Series UnknownLatest round
3Rounds and grants
Money by yearUSD, rounds and grants
2024$14M1 record
2019$500k1 record
2018$1.3M1 record
Largest rounds and grants
Sources: funding announcements, grant and company registers

Milestones

Each milestone is dated by its source: registers, filings, the press

Newsroom

Aug 182026
News · Pulse 2.0
Traws Pharma has structured up to $50 million of potential additional financing around specific regulatory and clinical milestones for its influenza program, directly connecting…
May 82026
Press release · The Manila Times
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (
Apr 152026
Press release · The Manila Times
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,
Apr 22026
Press release · The Globe and Mail
Detailed price information for Traws Pharma Inc (TRAW-Q) from The Globe and Mail including charting and trades.
Aug 8, 20252025
Press release · Nasdaq
--Traws Pharma, Inc., a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today anno…
Jun 3, 20252025
Press release · The Globe and Mail
Detailed price information for Traws Pharma Inc (TRAW-Q) from The Globe and Mail including charting and trades.
Sources: the outlets named on each headline, each story once